About This Video
On the Canadian Securities Exchange (CSE) Issuer Update series, part of this year’s Summit on Responsible Investment, James Black sits down with Nick Kadysh, CEO & President of PharmAla Biotech Holdings Inc. (CSE:MDMA), the world’s only commercial supplier of clinical-grade MDMA for PTSD treatment.
Nick shares PharmAla’s mission: providing safe, regulated access to MDMA-assisted therapy in Canada and Australia, developing novel MDMA analogs with improved safety profiles, and supporting global clinical trials exploring new uses for MDMA. Backed by real-world evidence showing remarkable patient outcomes, PharmAla’s work is transforming mental health care—and opening doors for regulatory change.
With new markets opening, including the EU and partnerships like Cortexa in Australia, PharmAla is expanding access to life-changing therapies while advancing research. The company is also pioneering tools like a prescriber portal and CME programs to support Canadian doctors and patients.
As Nick says, “What better thing can you imagine than giving people back a piece of their soul?”
Read the TranscriptAuto-generated by YouTube; names and terms may be misspelled.
Welcome everybody to another episode of an issuer update as part of this year's summit on responsible investment. Today I am pleased to be joined by Nick Kades who is the CEO of Formala, a listed company on Canadian Securities Exchange under the symbol MDMA. Nick, welcome to the show. I've eagerly been anticipating our conversation to talk about Formala Biotech holdings and some of the work you guys are doing.
So without further ado, maybe let the viewers know just just in general terms what you guys are doing at Formala. It's it's quite the story. Thanks. and listen, my pleasure to be here. so our ticker symbol is MDMA, which is very apt because that is what we do. So, Phmala is currently the world's only commercial supplier of clinical grade MDMA for the treatment of post-traumatic
stress disorder. So, we sell MDMA to doctors and patients in both Canada and Australia. Those are the two countries where, you know, you're able to to prescribe MDMA through various legal regulatory pathways. Then we supply clinical trials all over the world that are studying MDMA for all kinds of indications, not just PTSD. and then the third thing we do is we develop our own patented novel analoges and
molecules that are you know derivatives of MDMA and and related to MDMA but have like other benefits or effects. So we are both a manufacturer of a of a commercial drug and a researcher and developer a drug developer. Awesome. So again the reason you're on the summit for responsible investment is I think there's a huge social aspect to to what it is you're doing. I mean, you mentioned PTSD as a
as one of the problems you're trying to to help solve or at least address through through Yeah. So, maybe just talk a bit more about this MDMA assisted therapy really how it works and also you know the success you're having from your client's perspective. What what are they going through here? For sure. So, PTSD is really hard to treat. I mean I think sort of
the best-in-class treatments for PTSD as with a lot of psychiatric disorders is about 30%. So really what we do is we put you in therapy and hopefully we give you anti-depressants. Maybe we give you like cannabis to sort of take the edge off. But you know either the therapy helps or it doesn't. And in 70% of cases it doesn't. what a lot of people don't know is that MDMA, while it is
like a drug of abuse, yes, people are using it to party. But for about 30 years it's been researched as a potential treatment for PTSD and the results are nothing less than spectacular. so two phase three clinical trials have been completed. They've been published in nature. Those are done by an organization called MAPS which is the multiddisciplinary association for psychedelic studies and in those trials they found that
70% of patients basically after 3 months of therapy no longer have PTSD. It's like a cure and these are hard cases. These are people who've tried other treatments before and like you know no luck. So the results have been pretty spectacular. and you know because we're the only company that's actually treating patients today in the real world you know outside of clinical trials I can say with all honesty
that we've seen very very similar results in the real world which is amazing. So one of our customers Emiria which is an Australian firm recently released their first sort of trunch of data real world evidence of eight patients and what they saw is after 3 months people actually continue to get even better after they're done treatment after 3 months. So pretty remarkable stuff. Right. So do you go
through this treatment process once or is this an ongoing sort of treatment that you have to continue? Three months and you're done. It's it's just three months. So, it's not like a once a day pill. It's MDMA assisted therapy. So, you you never actually like you go into the therapist office, you take the MDMA, and then you go through therapy while you're under the influence of MDMA. But
MDMA happens to be sort of like the perfect drug to treat this one specific disorder. And it works remarkably well. H and so foreseeing that you you know phase three what is again what gets you through to completion of the phase trials and then to to executing a true go to market strategy with this drug. So we're actually opening new markets all the time. So we opened the
Australian market two years ago. Obviously we're we're here in Canada. So we're you know our strategy internally on on the generic MDMA is we are just you know we're opening markets as they open. you know we push a little bit but we don't try to sort of bust through the wall with our foreheads. We let regulators take the lead. we are trying to grow our current markets in
Australia and Canada as much as possible. and certainly there's a lot of need and a lot of patients that that need help there. So u that's a big focus for us and then just continuing to supply clinical trials. Eventually the the the base of clinical evidence becomes so overwhelming that it's very very hard for regulators to say no. and that's sort of that's our strategy on the generic MBMA side for the novel
molecules that we're developing. We are you know we're actively working towards clinical trials for those molecules but those are ones that we have patents on that we own whereas MDMMA is generic right so maybe talk a bit more about is that like Leno is that one of the products you've mentioned in your LEO is our MDMA product that's our generic MDMA product that's right that's for generic so talk about novel for a
second what's what's sort of the difference there what what are you guys working on in that in that context so so we have a number of new molecules and I will actually just give a lot of credit to our our research team so far formal has become really really adept at devel developing novel molecules in this specific space. We're highly specialized, but we can take so we
have we have what's called a QAR model, which is like a receptor binding model for your neurons in your brain. focusing in on the specific sort of the specific receptors that MDMA like molecules target. And then we have an AI model to figure out if we can make it in the real world because manufacturing these molecules is sometimes a challenge. And then we have an animal
lab at the University of Arkansas with Professor Bill Fanty's lab down there. So in about six months we can go from you know idea to development to manufacturing to getting it into rodents and beginning to build that like toxicological data set. and so our lead molecule ALA02 this is a patented analog of MDMA. It's better on toxicology cardiotox hypothermia some of the major adverse events of of MDMA. and
we are we have a partnership with the University of Sydney in Australia to do a phase 2 clinical trial and we are just trying to get some financing in place for that trial. We closed a small tranch of financing in in December but clinical trials are expensive and we try to do things as cheaply as possible to be honest with you. So looking for
the right partner to invest in that trial. Yeah. No, and we'll talk about that in a moment. you mentioned artificial intelligence and and keeping cost down. So obviously there's an analog there. Maybe just talk a bit more about how you know AI is helping in the drug discovery and phase triing pathway for you guys. So so people can understand that you know there's there's
clear utility here in using AI in this yeah I mean look one of the best use cases for AI is you develop these molecules right and and they're sort of they're sitting on a on a whiteboard somewhere you know you've drawn them out. In the past, what would happen is you would then go out and go to a wet chemistry lab and say like, "Make it, you know, just figure out how to make
it." And you would try and often times you would fail because a lot of the things that sound good and look good when you're drawing it on a on a board, you can't actually physically make it like the laws of chemistry will not permit it. and so that there prior to you know sort of the advent of sort of the computational AI models that we use you would just have to physically try
and and that's a very costly process. you use reagents you use people's time you have a chemistry lab that you need to sort of work out and you need to have very creative chemists who sort of can figure this out medical chemist. Now what we do is we basically say to the AI, hey, can you tell me if you can make this? And know like sort of with the
full body of chemistry knowledge at their disposal. some of these AI models now they're very highly specialized AI models for chemistry, but some of them can can basically give you an answer. so it definitely saves a lot of time and energy and money. Yeah. And in addition to that, you mentioned partnerships. So, especi specifically in Australia, joint venture with Cortexa. maybe just talk a bit more, you know, how did that,
relationship strike up and really maybe some of the differences of, you know, the Australian drug pathway versus maybe North America and some of the similarities that that we can relate back to the viewers. So, yeah. Yeah. So so the story on Australia is in 2023 so two years ago in February there was an announcement made that Australia would basically allow for MDMA assisted therapy for postraumatic stress
based on all of these clinical trials that we talked about and it really came out of the blue. but we moved very quickly like we're you know we're a small team we're a nimble team. we were there like you know six weeks later we're on the ground in Australia meeting with partners and we ended up partnering with a company called Vura. Vura at the time they were the number one
medical cannabis firm in Australia. in Australia there is no recreational cannabis unlike Canada. So it's very much they were a great partner. They continue to be a great partner. and so we put together Cortexo which is our joint venture down there. that's the organization that does all the MDMMA supply for the for the Australian sort of continent. and in terms of the differences between their their
approvals and ours in basically the crux of it is in Canada we approve individual patients. So Health Canada looks at a patient's file and says yes to you, no to you. In Australia they approve doctors. So you as a psychiatrist get approved to prescribe and once you're approved by it's you know the TGA which is the regulator and the Royal Australian College of Psychiatry, Australia New Zealand College of
Psychiatry. once they approve you, you can write as many scripts as you want. and obviously in terms of what I believe is the better regulatory strategy, I think the Australian one is better because I don't love the idea of sort of unelected bureaucrats being between doctors and patients. It's not the best. Understood. Let's just take a quick step back. you know what what
brought you to this type of business and and what drives you through this business? What what keeps you passionate? Because we know as entrepreneurs you know every day is different. it's always some days are harder than others and there's always a central mission or vision usually that drives people like yourself to to pursue these businesses because there's there's good and bad markets as well.
just curious from your perspective what what what keeps you motivated to to pursue these this mission that you're on? well look I I will say you know you talked about good and bad times being a biotech company right now I think we're at like the sort of the lowest point like the XBI which is the biotech index is like maybe at the lowest point in like human history. So
talk about highs and lows. and we've done we've done very well all things considered. you know, we didn't raise a lot of capital and we've built a like a revenue generating successful business. We've been growing at like 100% a year for the last two years trying to make it three this year. and in 2023 when we opened the Australian market, we were actually the number one growth stock in
Canada. So, like we've done very very well regardless of sort of the market conditions. but no, look, you talk about social impact. I tell this story a lot but I'll tell it again because it's I never get tired of it. the first guy to ever get approved in Canada for MDMMA assisted therapy. After he did his first treatment, he reached out to us and said like, "I
gotta talk to you, Nick. I got to talk to you and tell you how it went." Now, as a pharmaceutical manufacturer, you really don't want to talk to patients. Everything they say to you has to kept be kept in like this black box of patient information, you know. And so, I was very hesitant, but he was very insistent. and and so we get on the phone and I got to be honest, I was
very afraid. I was afraid this guy's going to say like your drug did nothing for me. It was all crap, you know. and and he said like the the words he used was you gave me back a piece of my soul that I thought was gone forever and I'm not all the way better yet, but I'm way better than I was before and I'm you know and I know that I'll be even better
after the second treatment and the third. and and funny enough, but that's exactly what we see in the data, you know, across the patient cohort. And so, you know, what better what better thing can you imagine than that to get you up in the morning? I mean, that's just it for me. Yeah, absolutely. I mean, we we've all known people who've been through stuff and stuff that they
can't get through on their own and they need help and this is another avenue for sure. as best as you can relay, I mean, what what do you have in mind for the rest of the year? We and I should note that we are recording this and and actually going to have this air and debut during mental health awareness week. So, I just wanted to
make that Yeah. known. But looking ahead for the rest of the year, Nick, what what what are some of the milestones you're you're seeking to achieve or working towards that you can share? Yeah. So, we're looking So, look, number one, this year we opened a new market for us, which is the European Union. So, we signed our first exclusive distribution partnership in Europe. that's with a company called Duche
Pharma in the Netherlands. the Netherlands we see as a very viable sort of market for MDMA because a state commission in the Netherlands has already strongly recommended legalization of MDMMA for medical purposes. so that that's in the in the rearview mirror, but we are always looking to open new markets at our pace that we like to set is at least one per
year new market. So we have a couple of others that we're we're looking at. hope to be able to share news soon, but of course this is all at the sort of at the at the discretion of regulators. So I I never pre-announce anything on that front. the other big thing that we're looking at is developing new tools for doctors and patients to access these therapies here
in Canada. So in Canada, we we developed the prescribers portal. This is to help the doctors fill out the health Canada paperwork that they need to get this this to this medication to their patients. we're also looking to partner with an organization to launch the first continuing medical education program. so that will, you know, additional information for doctors, give them comfort that they can
prescribe this medication in Canada. and then, just continue to drive forward on research. So, we've announced a couple of really big partnerships this year, including we're going to be the first company to actually provide, MDMMA to the US military to do a clinical trial. so I never thought I would string the the following words together, but we are going to be selling MDMA to the US military.
Yeah. Well, I mean the the military is a clear and obvious customer in Veterans Affairs. no doubt. So, this actually for this is for active duty military personnel with PTSD. So, it is a clinical trial of course, but but really really amazing and interesting work that they're going to be doing. That's that's that's amazing. personally that's amazing. My my father was in the military and I can
attest to the fact that you meet people they've been through a lot of stuff and they certainly they need help during and after their careers of service. Nick, just for those following the story, where where do you want to direct them to as things continue to roll out for you guys? Yeah, well I I mean obviously to the CSC where we trade under the ticker symbol MDMA.
our website is www.farmmala.ca. and you know we're we're pretty active on social as well so follow us on you know Twitter and LinkedIn. That's fantastic Nick. Thanks so much for your time today and for those watching this was the CSC's issuer update but also a part of our summit on responsible investment and as as mentioned earlier this is being rolled out during mental health
awareness week as well. So a lot of great resources shared today Nick and thanks again and best of luck to you in your endeavor. Thanks so much for having me.



